Production (Stage)
Palvella Therapeutics, Inc.
PVLA
$25.40
$1.918.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 206.32% | 91.56% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.35% | 19.66% | -- | -- | -- |
| Operating Income | -122.35% | -19.66% | -- | -- | -- |
| Income Before Tax | -200.94% | -167.33% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -200.94% | -167.33% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.94% | -167.33% | -- | -- | -- |
| EBIT | -122.35% | -19.66% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -363.21% | -531.38% | -- | -- | -- |
| Normalized Basic EPS | -197.98% | -868.20% | -- | -- | -- |
| EPS Diluted | -361.03% | -532.89% | -- | -- | -- |
| Normalized Diluted EPS | -190.40% | -912.88% | -- | -- | -- |
| Average Basic Shares Outstanding | 76.79% | 5.87% | -- | -- | -- |
| Average Diluted Shares Outstanding | 75.70% | 5.33% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |